An intravenous glyco-humanized polyclonal antibody (biologic immunotherapy) engineered with human-like glycosylation to reduce immunogenic carbohydrate residues and enhance Fc effector function; expected to mediate tumor cell killing via ADCC, ADCP, and CDC in advanced/metastatic solid tumors.
Glyco‑humanized polyclonal antibody that binds multiple tumor epitopes and is engineered with human-like Fc glycosylation to enhance Fc effector function and reduce immunogenic carbohydrates; kills tumor cells via Fc-dependent mechanisms including ADCC (via Fcγ receptor–bearing NK cells), ADCP (macrophages), and CDC (classical complement activation).
NO
INDIRECT
XON7 binds tumor antigens and uses its Fc to engage Fcγ receptors (including CD32B) on immune effector cells, triggering ADCC/ADCP and CDC to kill antigen-positive tumor cells; CD32B+ cells are effectors, not targets, and are not directly killed.
An intravenous glyco-humanized polyclonal antibody (biologic immunotherapy) engineered with human-like glycosylation to reduce immunogenic carbohydrate residues and enhance Fc effector function; expected to mediate tumor cell killing via ADCC, ADCP, and CDC in advanced/metastatic solid tumors.
Glyco‑humanized polyclonal antibody that binds multiple tumor epitopes and is engineered with human-like Fc glycosylation to enhance Fc effector function and reduce immunogenic carbohydrates; kills tumor cells via Fc-dependent mechanisms including ADCC (via Fcγ receptor–bearing NK cells), ADCP (macrophages), and CDC (classical complement activation).
NO
INDIRECT
The antibody binds tumor antigens via Fab and engages CD64 (Fc gamma receptor I) on macrophages/monocytes through its Fc to trigger ADCC/ADCP and complement (CDC) against antibody-coated tumor cells; CD64+ cells act as effectors, not targets.
An intravenous glyco-humanized polyclonal antibody (biologic immunotherapy) engineered with human-like glycosylation to reduce immunogenic carbohydrate residues and enhance Fc effector function; expected to mediate tumor cell killing via ADCC, ADCP, and CDC in advanced/metastatic solid tumors.
Glyco‑humanized polyclonal antibody that binds multiple tumor epitopes and is engineered with human-like Fc glycosylation to enhance Fc effector function and reduce immunogenic carbohydrates; kills tumor cells via Fc-dependent mechanisms including ADCC (via Fcγ receptor–bearing NK cells), ADCP (macrophages), and CDC (classical complement activation).
NO
INDIRECT
XON7 binds tumor antigens via its Fab; its Fc engages C1q to activate complement (CDC) and Fcγ receptors for ADCC/ADCP, killing antibody‑coated tumor cells. C1q (A chain) is an effector ligand, not a direct target, so cells expressing it are not directly killed.
An intravenous glyco-humanized polyclonal antibody (biologic immunotherapy) engineered with human-like glycosylation to reduce immunogenic carbohydrate residues and enhance Fc effector function; expected to mediate tumor cell killing via ADCC, ADCP, and CDC in advanced/metastatic solid tumors.
Glyco‑humanized polyclonal antibody that binds multiple tumor epitopes and is engineered with human-like Fc glycosylation to enhance Fc effector function and reduce immunogenic carbohydrates; kills tumor cells via Fc-dependent mechanisms including ADCC (via Fcγ receptor–bearing NK cells), ADCP (macrophages), and CDC (classical complement activation).
NO
INDIRECT
XON7 binds tumor antigens on cancer cells and kills them via Fc-mediated ADCC/ADCP and complement-dependent cytotoxicity (C1q activation). Complement C1q B chain is an effector component, not the binding target; cells expressing it are not directly killed by the drug.
An intravenous glyco-humanized polyclonal antibody (biologic immunotherapy) engineered with human-like glycosylation to reduce immunogenic carbohydrate residues and enhance Fc effector function; expected to mediate tumor cell killing via ADCC, ADCP, and CDC in advanced/metastatic solid tumors.
Glyco‑humanized polyclonal antibody that binds multiple tumor epitopes and is engineered with human-like Fc glycosylation to enhance Fc effector function and reduce immunogenic carbohydrates; kills tumor cells via Fc-dependent mechanisms including ADCC (via Fcγ receptor–bearing NK cells), ADCP (macrophages), and CDC (classical complement activation).
NO
INDIRECT
C1q C chain is a complement component that binds the antibody Fc to activate CDC against antibody-coated tumor cells. XON7 does not target C1q; cells expressing C1q are not directly killed.